Organoids Market Size Report | Analysis and Forecast 2030

[Research Report] The organoids market is expected to grow from US$ 2,507.28 million in 2022 to US$ 12,206.15 million by 2030; it is estimated to record a CAGR 21.9% during 2022–2030.

Market Insights and Analyst View:

The increasing demand for tumor modeling and biobanking and growing adoption of personalized drugs are the among the factors driving the organoids market expansion. Additionally, rising focus on developing alternatives for animal testing models support are expected to boost the organoids market growth. Animal models are used widely in biomedical research for human-specific diseases. However, various drug toxicology studies demonstrate that animal models cannot always predict human drug response. Therefore, to develop alternative testing models that can provide an environment with full equivalence to the human body, various institutes are developing alternative methods for drug development and biomedical research. Also, the use of organoids has increased as an alternative to animal testing after placing restrictions on animal testing by different governments.

The organoids market key players are focusing on strategic initiatives by collaborations to expand their geographic reach and enhance capacities to cater to a large customer base. For instance, in August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have signed an agreement to use tissue-derived organoids—including lung, intestinal, and liver organoids—in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. Factors such as increasing demand for tumor modeling and biobanking and growing adoption of personalized drugs, bolstering the organoids market growth. Additionally, rising focus on developing alternatives for animal testing models are driving the organoids market growth.

Growth Drivers and Challenges:

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Over the past few decades, organoids have been generated from diverse human cancers associated with breast, colon, pancreas, prostate, bladder, and liver. Studies involving these models help in providing key facts about these malignancies. Due to constant advancements in the current scenario, tumoroid lines are increasingly being passed in vitro, opening new paths for a range of downstream applications. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines. Further, recent research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is propelling the global organoids market.

Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, such innovations are driving the market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Organoids Market: Strategic Insights

Market Size Value in	US$ 2,507.28 million in 2022
Market Size Value by	US$ 12,206.15 million by 2030
Growth rate	CAGR 21.9% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Organoids Market Segmentation and Scope:

The “Global Organoids Market” is segmented based on type, application, source, and geography. The organoids market, by type, is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. Based on application, the organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. By source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. Geographically, the organoids market is divided into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Based on type, the organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment accounted for the largest market share in 2022 and is expected to register a CAGR of 21.6% during the forecast period. The market position of this segment is due to the prevalence of inflammatory bowel diseases (IBDs). IBDs, such as Crohn's disease (CD) and ulcerative colitis (UC), are common worldwide. In the last decade, there has been a dramatic shift in the availability of tools and model systems that are used to study the intestinal epithelium. The development and adoption of intestinal organoid cultures have been the core of this movement. Simultaneously, various experimental techniques—including novel genetic manipulation tools, in vitro disease modeling approaches, innovative co-culture systems with autologous cell types or bacteria, and viral infection models—were developed to evaluate a scientifically synergistic effect with intestinal organoid cultures.  The aforementioned factors are responsible for driving the organoids market growth for the segment.

Based on application, the organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2020 and is likely to grow at the highest rate during the forecast period. Human organoid cultures can be used to study human development and model diseases with the same depth of analysis that is customary for research with nonhuman model organisms. Technological advancements in 3D bioprinting have shown a massive potential to facilitate organ development, as the time required for organoid culturing is much less than traditional tissue culture methods. Patient-derived human organoid studies may create new opportunities in the fields of tissue engineering and regenerative medicine, generating knowledge and tools for preclinical testing in drug development studies. The growth of the organoids market for developmental biology applications is attributed to the acceptance received by organoids as the primary investigative research tool in human developmental biology. Moreover, organoids derived from embryonic stem cells offer a complete understanding of embryonic process development and insights into stem cell development.

Based on source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the market in 2020 and is likely to grow at a higher rate during the forecast period. Induced pluripotent stem cells (iPSCs) are perceived as an essential resource for regenerative medicine to replace diseased or damaged tissues. iPSCs have numerous biomedical applications in fundamental research, drug screening, toxicological studies, disease modeling, and cell therapy. These cells can be potentially used in cell replacement therapy to treat patients with cellular diseases. Thus, they are widely used for developing an organoid in vitro. In addition, pluripotent cells are used in biobanking to preserve patient-derived stem cells in various applications, which can be used in research and therapeutics. In November 2017, Cincinnati Children's scientists launched the Center for Stem Cell and Organoid Medicine (CuSTOM), which uses pluripotent stem cells to mimic organoids.      

Organoids Market, by Source– 2020 and 2028

Access Data

Regional Analysis:

Based on geography, the organoids market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2020, North America held the largest share of the global organoids market, and Asia Pacific is estimated to register the highest CAGR during the forecast period. North America is the largest market for organoids in biobanking, with the US holding the largest market share, followed by Canada. The US market is primarily driven by increasing research and development activities, rising demand for tissue engineering and organ transplantation, and high adoption rate of organoids. Thus, owing to the wide range of benefits, there is a significant demand for organoids in the US. Research funding and venture capital investments have significantly increased the development of human organoids. In November 2020, Megan McCain of the USC Viterbi Department of Biomedical Engineering collaborated with Giorgia Quadrato and Leonardo Morsut of the USC Keck School of Medicine's Department of Stem Cell Biology and Regenerative Medicine on a four-year, US$ 1.5 million National Science Foundation-funded project. With this project, the firm looks forward to improving the process of developing brain organoids and making end products more consistent and reliable for brain researchers. Similarly, in 2019, the US National Institutes of Health allocated a total funding budget of US$ 39.1 billion, of which US$ 6.25 billion (16%) was invested into cancer research and US$ 701 million to breast cancer research. Additionally, UC San Diego researchers are developing human organoids—miniaturized, 3D versions of an organ produced from reprogrammed stem cells in the lab. These models, sometimes called “mini-brains” or “organs-in-a-dish,” have empowered scientists to study biological functions, diseases, and treatments more realistically and in greater detail. Hence, apart from the demand for organoids, the growing research activities to reduce cancer prevalence is also driving the organoids market growth in North America.   

Industry Developments and Future Opportunities: 

Various initiatives taken by key players operating in the global organoids market are listed below:

1. In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in biotechnology and scientific instruments.
2. In March 2023, Molecular Devices, LLC. collaborated with HUB Organoids (HUB) for continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition. Under the terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types such as the heart and brain.
3. In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.    

COVID-19 Impact:

Stem-cell-derived organoid models have received high focus on a new treatment and research method for COVID-19. Additionally, clinical studies reveal that various organoids derived from stem cells offer an ideal and sufficient model to explore the possibility and mechanism of SARS-CoV-2 infecting multiple organs that can better serve clinical treatment research. Moreover, stem cell therapy amid the pandemic is not only available for severe COVID-19 patients but also for those who recovered from severe COVID-19 complications to repair damaged lungs making it an ideal treatment option.

Several research groups have successfully shown that SARS-CoV-2 can infect and propagate in primary human organoids derived from the liver and gut and in pluripotent stem cell-derived organoids modeling blood vessels in the kidney. Moreover, it has been shown that the viral infection of the human blood vessel and kidney organoids can be inhibited by human recombinant soluble ACE2, a drug candidate initially developed for SARS-CoV-2. Structural studies of the spike proteins of SARS-CoV-2 and SARS-CoV bound to ACE2 predicted a similar result. These studies have provided additional evidence that human organoids can serve as a useful research platform for studying human diseases, including the outbreak of new viruses such as SARS-CoV-2. Further, strategic activities by the researcher, along with funding, will have a positive impact on the market. For instance, the Government of Canada is investing US$ 27 million in coronavirus research. The investment will support 47 projects across two research areas to ensure a balanced research response. Human and animal organoids are now proving their value as an experimental virology platform. Usage of the organoid models to reveal how the COVID-19 virus affects several intestinal cells is expected to drive organoids in research. Scientists have been using these systems for the testing and identification of promising medications. Thus, the collaboration is expected to impact the organoids market in the coming few years positively.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global organoids market are STEMCELL Technologies Inc., Cellesce Ltd, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, 3Dnamics Inc., Thermo Fisher Scientific Inc, Corning Inc, Merck KGaA, and InSphero. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which provides them to serve a large set of customers and subsequently increases their market share.